Use of metformin in the treatment of polycystic ovary syndrome

Women's Health

Volumn 6, Issue 4, 2010, Pages 577-593

  Genazzani, Alessandro D ^a   Ricchieri, Federica ^a   Lanzoni, Chiara ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

hyperandrogenism; infertility; insulin resistance; metformin; obesity; PCOS; polycystic ovary syndrome; Type 2 diabetes

Indexed keywords

ANDROGEN; ANDROSTENEDIONE; ESTROGEN; FOLLITROPIN; GLUCOSE; HYDROXYPROGESTERONE; INSULIN; LUTEINIZING HORMONE; METFORMIN; PRASTERONE SULFATE; PROLACTIN; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE;

ABDOMINAL DISCOMFORT; BODY MASS; CONSTIPATION; DIARRHEA; DIET RESTRICTION; DRUG ABSORPTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MEGADOSE; ECLAMPSIA; FEMALE; FEMALE FERTILITY; FEMALE INFERTILITY; FLATULENCE; GLUCOSE TRANSPORT; HEARTBURN; HEREDITY; HUMAN; HYPERANDROGENISM; HYPOTHALAMUS HYPOPHYSIS GONAD SYSTEM; INDIGESTION; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; INSULIN SYNTHESIS; LACTIC ACIDOSIS; MATERNAL HYPERTENSION; MEDICAL DECISION MAKING; MENSTRUAL CYCLE; MENSTRUAL IRREGULARITY; METABOLIC SYNDROME X; MOOD; NAUSEA AND VOMITING; NON INSULIN DEPENDENT DIABETES MELLITUS; OVARY POLYCYSTIC DISEASE; OVULATION; PHYSICAL ACTIVITY; PREGNANCY; PREGNANCY DIABETES MELLITUS; QUALITY OF LIFE; REVIEW; RISK REDUCTION; TREATMENT DURATION; WAIST HIP RATIO; WEIGHT REDUCTION;

ADAPTATION, PSYCHOLOGICAL; BODY MASS INDEX; ENDOCRINE SYSTEM; FEMALE; HUMANS; HYPERANDROGENISM; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; MENSTRUATION DISTURBANCES; METFORMIN; POLYCYSTIC OVARY SYNDROME; PREGNANCY; QUALITY OF LIFE;

EID: 77954420211     PISSN: 17455057     EISSN: 17455065     Source Type: Journal    
DOI: 10.2217/whe.10.43     Document Type: Review

References (159)

1. Velazquez EM, Mendoza S, Hamer T, Sosa F, Glueck CJ: Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism 43, 647-654 (1994). (Pubitemid 24145474)
2. Carmina E, Lobo RA: Polycystic ovary syndrome: arguably the most common endocrinopathy is associated with signifcant morbidity in women. J. Clin. Endocrinol. Metab. 84, 1897-1899 (1999). (Pubitemid 30647006)
3. Zborowski JV, Cauley JA, Talbott EO et al.: Bone mineral density, androgens, and the polycystic ovary: the complex and controversial issue of androgenic infuence in female bone. J. Clin. Endocrinol. Metab. 85, 3496-3506 (2000).
4. Carmina E: Genetic and environmental aspects of polycystic ovary syndrome. J. Endocrinol. Invest. 26, 1151-1159 (2003). (Pubitemid 38195457)
5. Zawadzki JK, Dunaif A: Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Polycystic Ovary Syndrome. Dunaif A, Givens JR, Haseltine FP, Merriam GR (Eds). Blackwell, MA, USA, 337-384 (1992).
6. Polson DW, Adams J, Wadsworth J, Franks S: Polycystic ovaries-a common fnding in normal women. Lancet 1, 870-872 (1988). (Pubitemid 18092411)
7. Azziz R, Carmina E, Dewailly D et al.; Androgen Excess Society: Position statement: criteria for defning polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J. Clin. Endocrinol. Metab. 91, 4237-4245 (2006). (Pubitemid 44833391)
8. Palomba S, Falbo A, Zullo F, Orio F: Evidence-based and potential benefts of metformin in the polycycstic ovary syndrome: a comprehensive review. Endocr. Rev. 30, 1-50 (2009).
9. Palomba S, Falbo A, Orio F, Zullo F: Insulin sensitizing agents and reproductive function in polycystic ovary syndrome patients. Curr. Opin. Obstet. Gynecol. 20, 364-373 (2008).
10. Deligeoroglou E, Kouskouti C, Christopoulos P: The role of genes in the polycystic ovary syndrome: predisposition and mechanism. Gynecol. Elndocrinol. 25, 603-609 (2009).
11. Hirschberg AL: Polycystic ovary syndrome, obesity and reproductive implications. Womens Health 5, 529-540 (2009).
12. Doi SA: Neuroendocrine dysfunction in PCOS: a critique of recent reviews. Clin. Med. Res. 2008 6: 47-53.
13. Vrbikova J, Hainer V: Obesity and polycystic ovary syndrome. Obes. Facts 2, 26-35 (2009).
14. Kalro BN, Loucks TL, Berga SL: Neuromodulation in polycystic ovary syndrome. Obstet. Gynecol. Clin. North Am. 28, 35-62 (2001).
15. Rebar R, Judd HL, Yen SS, Rakoff J, Vandenberg G, Naftolin F: Characterization of the inappropriate gonadotropine secretion in polycystic ovary syndrome. J. Clin. Invest. 57, 1320-1329 (1976).
16. Barnes RB, Rosenfeld RL, Burstein S, Ehrmann DA: Pituitary ovarian responses to nafarelin testing in the polycystic ovary syndrome. N. Engl. J. Med. 320, 559-565 (1989). (Pubitemid 19070540)
17. Genazzani AD, Petraglia F, Pianazzi F, Volpogni C, Genazzani AR: The concomitant release of androstenedione with cortisol and luteinizing hormone pulsatile releases distinguishes adrenal from ovarian hyperandrogenism. Gynecol. Endocrinol. 7, 33-41 (1993). (Pubitemid 23146623)
18. Nelson VL, Qin KN, Rosenfeld RL, et al.: The biochemical basis for increased testosterone production in theca cells propagated from patients with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 86, 5925-5933 (2001).
19. Novak ER, Goldberg B, Jones GS, O'Toole RV: Enzyme histochemistry of the menopausal ovary associated with normal and abnormal endometrium. Am. J. Obstet. Gynecol. 93, 669-682 (1965).
20. Plouffe L Jr: Disorders of excessive hair growth in the adolescent. Obstet. Gynecol. Clin. North Am. 27, 79-99 (2000).
21. Chittenden BG, Fullerton G, Maheshwari A, Bhattacharya S: Polycystic ovary syndrome and the risk of gynaecological cancer: a systematic review. Reprod. Biomed. Online 19, 398-405 (2009).
22. Ciaraldi TP, el-Roeiy A, Madar Z et al.: Cellular mechanisms of insulin resistance in polycystic ovarian syndrome. J. Clin. Endocrinol. Metab.ol 75, 577-583 (1002).
23. Kirschner MA, Samojlik E, Dreika M et al.: Androgen-estrogen metabolism in women with upper body versus lower body obesity. J. Clin. Endocrinol. Metab. 70, 473-479 (1990). (Pubitemid 20056486)
24. Peiris AN, Mueller RA, Struve MF et al.: Relationship of androgenic activity to splanchnic insulin metabolism and peripheral glucose utilization in premenopausal women. J. Clin. Endocrinol. Metab. 64, 162-169 (1987).
25. Rebuffe-Scrive M, Marin P, Bjorntorp P: Effect of testosterone on abdominal adipose tissue in men. Int. J. Obes. 15, 791-795 (1991).
26. Pasquali R, fabbri R, Venturoli S et al.: Effect of weight loss and antiandrogenic therapy on sex hormone blood levels and insuline resistance in obese patients with polycystic ovaries. Am. J. Obstet. Gynecol. 154, 139-144 (1986). (Pubitemid 16106667)
27. Dunaif A, green G, Futterweit W, Dobrjansky A: Suppression of hyperandrogenism does not improve peripheral or hepatic insulin resistance in polycystic ovary syndrome J. Clin. Endocrinol. Metab. 70, 699-704 (1990). (Pubitemid 20092446)
28. Barbieri RL: The role of adipose tissue and hyperinsulinemia in the development of hyperandrogenism in women. In: Adipose Tissue and Reproduction. Karger, Basal, 42-57 (1990).
29. Conway GS, Jacobs HS, Holly JM, Wass JA: Effects of LH, insulin, insulin-like growth factor I and insulin-like growth factor small binding protein I in the polycystic ovary syndrome. Clin. Endocrinol. 33, 593-603 (1990). (Pubitemid 20346607)
30. Conway GS, Honours J W, Jacobs HS: Heterogeneity of the polycystic ovary syndrome: clinical, endocrine and ultrasound features in 556 patients. Clin. Endocrinol. 30, 459-470 (1989).
31. Dunaif A, Givens JR, Haseltine F et al.: The Polycystic Ovary Syndrome. Blackwell Scientifc, MA, USA (1992).
32. Mattsson LA, Gullberg G, Hamberger L, Samsioe G, Silverstolpe G: Lipid metabolism in women with polycystic ovary syndrome: possible implications for an increased risk of coronary heart disease. Fertil. Steril. 42, 579-584 (1984). (Pubitemid 14021774)
33. Wild RA, Painter PC, Coulson PB, Carruth KB, Ranney GB: Lipoprotein lipid concentrations and cardiovascular risk in women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 61, 946-951 (1985).
34. Muniyappa R, Montagnani M, Koh KK, Quon MJ: Cardiovascular actions of insulin. Endocr. Rev. 28, 463-491 (2007). (Pubitemid 47236334)
35. Shaw LJ, Bairey Merz CN, Azziz R et al.: Postmenopausal women with a history of irregular menses and elevated androgen measurements at high risk for worsening cardiovascular event-free survival: results from the National Institutes of Health-National Heart, Lung, and Blood Institute sponsored Women's Ischemia Syndrome Evaluation. J. Clin. Endocrinol. Metab. 93, 1276-1284 (2008). (Pubitemid 351519721)
36. Carmina E: Cardiovascular risk and events in polycystic ovary syndrome. Climacteric 12(Suppl. 1), 22-25 (2009).
37. Eckel RH, Alberti KG, Grundy SM, Zimmet PZ: The metabolic syndrome. Lancet 375(9710), 181-183 (2010).
38. Grundy SM: Metabolic syndrome: part II. Endocrinol. Metab. Clin. North Am. 33(3), xi-xiii (2004).
39. Cornier MA, Dabelea D, Hernandez TL et al.: The metabolic syndrome. Endocr. Rev. 29, 777-822 (2008).
40. Franks S: Polycystic ovary syndrome. N. Engl. J. Med. 333, 853-861 (1995).
41. Wild S, Pierpoint T, Mckeigue P: Cardiovascular disease in women with polycystic ovary syndrome at long term follow up: a retrospective cohort study. Clin. Endocrinol. 52, 595-600 (2000). (Pubitemid 30337085)
42. Dockras A, Bochner M, Holinrake E: Screening women with polycystic ovary syndrome for metabolic syndrome. Obstet. Gynecol. 106, 131-137 (2005). (Pubitemid 40898445)
43. Gluek CJ, Papanna R, Wang P: Incidence and treatment of metabolic syndrome in newly referred women with confrmed polycistic ovarian syndrome. Metabolism 52, 908-915 (2003). (Pubitemid 36957780)
44. Apridonidze T, Essah PA, Iuorno MJ: Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J. Clin. Endocrin. Metab. 90, 1929-1935 (2005). (Pubitemid 40586223)
45. Chen MJ, Yang WS, Yang JH: Low sex hormone binding globulin is associated with low high density lipoprotein cholesterol and metabolic syndrome in women with PCOS. Hum. Reprod. 21, 2266-2271 (2006).
46. Guzick DS, Talbott EO, Sutton Tyrrell K, Herzog HC, Kuller LH, Wolfson SK: Carotid atherosclerosis in women with polycystic ovary syndrome: initial results from a case-control study. Am. J. Obstet. Gynecol. 174, 1224-1229 (1996).
47. Talbott EO, Guzick DS, Sutton-Tyrrell K, McHughPemu KP, Zborowski JV, Remsberg KE: Evidence for association between polycystic ovary syndrome and premature carotid atherosclerosis in middle-aged women. Arterioscler. Thromb. Vasc. Biol. 20, 2414-2421 (2000).
48. Luscher TF, Richard V, Tshudi M, Yang ZH, Boulanger C: Endothelial control of vascular tone in large and small coronary arteries. J. Am. Coll. Cardiol. 15, 519-527 (1990). (Pubitemid 20061474)
49. Vita JA, Treasure CB, Nabel EG, McLenachan JM, Fish RD, Yeung AC: Coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease. Circulation 81, 491-497 (1990). (Pubitemid 20055957)
50. Legro RS: Polycystic ovary syndrome and cardiovascular disease: a premature association? Endocr. Rev. 24, 302-312 (2003). (Pubitemid 36724372)
51. Ehrmann DA, Barnes RB, Rosenfeld RL, Cavaghan MK, Imperial J: Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 22, 141-146 (1999). (Pubitemid 29028311)
52. Palomba S, Russo T, Orio F Jr et al.: Uterine effects of metformin administration in anovulatory women with polycystic ovary syndrome. Hum. Reprod. 21, 457-465 (2006). (Pubitemid 43159923)
53. Dunaif A: Insulin resistance and the polycystic ovary syndrome: mechanism and implication for pathogenesis. Endocr. Rev. 18, 774-800 (1997). (Pubitemid 28009567)
54. Lillioja S, Mott D, Spraul M, Ferraro R, Foley JE, Ravussin E: Insulin resistance and insulin secretory dysfunction as precursors of non-insulin dependent diabetes mellitus. N. Engl. J. Med. 329, 1988-1992 (1993).
55. Dunaif A, Segal KR, Futterweit W, Dobrjansky A: Profound peripheral insulin resistance, independent of obesity, polycystic ovary syndrome. Diabetes 38, 1165-1174 (1989). (Pubitemid 19250404)
56. DeUgarte CM, Bartolucci AA, Azziz R: Prevalence of insulin resistance in the polycystic ovary syndrome using the homeostasis model assessment. Fertil. Steril. 83, 1454-1460 (2005). (Pubitemid 40615820)
57. Dunaif A, Segal KR, Shelley DR, Green G, Dobrjansky A, Licholai T: Evidence for distinctive and intrinsic defects in insulin action in polycystic ovary syndrome. Diabetes 41, 1257-1266 (1992).
58. Holte J, Bergh T, Berne C, Wide L, Lithell H: Restored insulin sensitivity but persistently increased early insulin secretion after weight loss in obese women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 80, 2586-2593 (1995).
59. Patel K, Coffer MS, Dahan MH et al.: Increased luteinizing hormone secretion in women with polycystic ovary syndrome is unaltered by prolonged insulin infusion. J. Clin. Endocrinol. Metab. 88, 5456-5461 (2003). (Pubitemid 37452754)
60. Genazzani AD, Battaglia C, Malavasi B, Strucchi C, Tortolani F, Gamba O: Metformin dministration modulates and restores luteinizing hormone spontaneous episodic secretion and ovarian function in nonobese patients with polycystic ovary syndrome. Fertil. Steril. 81, 114-119 (2004). (Pubitemid 38058335)
61. Genazzani AD, Lanzoni C, Ricchieri F, Baraldi E, Casarosa E, Jasonni VM: Metformin administration is more effective when non-obese patients with polycystic ovary syndrome show both hyperandrogenism and hyperinsulinemia. Gynecol. Endocrinol. 23, 146-152 (2007). (Pubitemid 46570211)
62. Skov V, Glintborg D, Knudsen S et al.: Reduced expression of nuclear-encoded genes involved in mitochondrial oxidative metabolism in skeletal muscle of insulin-resistant women with polycystic ovary syndrome. Diabetes 56, 2349-2355 (2007). (Pubitemid 47358242)
63. Hsueh AJ, Billig H, Tsafriri A: Ovarian follicle atresia: a hormonally controlled apoptotic process. Endocr. Rev. 15, 707-724 (1994).
64. Nieuwenhuis-Ruifrok AE, Kuchenbecker WK, Hoek A, Middleton P, Norman RJ: Insulin sensitizing drugs or weight loss in women of reproductive age who are overweight or obese: systematic review and meta-analysis. Hum. Reprod. Updat. 15, 57-68 (2009).
65. Bailey CJ, Turner RC: Metformin. N. Engl. J. Med. 334, 574-579 (1996).
66. Stumvoll M, Nurjhan N, Perriello G, Dailey G, Gerich JE: Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N. Engl. J. Med. 333, 550-554 (1995).
67. Matthaei S, Hamann A, Klein HH: Evidence that metformin increases insulin-stimulated glucose transport by potentiating insulin-induced translocation of glucose transporters from an intracellular pool to the cell surface in rat adipocytes. Horm. Metab. Res. 26, S34-S41 (1992). (Pubitemid 23017864)
68. La Marca A, Morgante G, Paglia T, Ciotta L, Cianci A, De Leo V: Effects of metformin on adrenal steroidogenesis in women with polycystic ovary syndrome. Fertil. Steril. 72, 985-989 (1999). (Pubitemid 29364624)
69. Cosma M, Swiglo BA, Flynn DN et al.: Insulin sensitizers for the treatment of hirsutism: a systematic review and metaanalyses of randomized controlled trials. J. Clin. Endocrinol. Metab. 93, 1135-1142 (2008). (Pubitemid 351519697)
70. Budak E, Fernández Sánchez M, Bellver J, Cerveró A, Simón C, Pellicer A: Interactions of the hormones leptin, ghrelin, adiponectin, resistin, and PYY3-36 with the reproductive system. Fertil. Steril. 85, 1563-1581 (2006). (Pubitemid 43816423)
71. Dunn CJ, Peters DH: Metformin. A review of its pharmacological properties and therapeutic use in non-insulin-dependent diabetes mellitus. Drugs 49, 721-749 (1995).
72. Palomba S, Falbo A, Russo T et al.: Insulin sensitivity after metformin suspension in normal-weight women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 92, 3128-3135 (2007). (Pubitemid 47236381)
73. Nestler JE, Stovall D, Akhter N, Iuorno MJ, Jakubowicz DJ: Strategies for the use of insulin-sensitizing drugs to treat infertility in women with polycystic ovary syndrome. Fertil. Steril. 7 7, 209-215 (2002). (Pubitemid 34083541)
74. Nestler JE: Metformin for the treatment of the polycystic ovary syndrome. N. Engl. J. Med. 358, 47-54 (2008).
75. Diamanti-Kandarakis E, Christakou CD, Kandaraki E, Economou FN: Metformin: an old medication of new fashion: evolving new molecular mechanisms and clinical implications in polycycstic ovary syndrome. Eur. J. Endocrinol. 162, 193-212 (2010).
76. Palomba S, Orio F Jr, Falbo A et al.: Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the frst-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 90, 4068-4074 (2005). (Pubitemid 41058174)
77. Zain MM, Jamaluddin R, Ibrahim A, Norman RJ: Comparison of clomiphene citrate, metformin, or the combination of both for frst-line ovulation induction, achievement of pregnancy, and live birth in Asian women with polycystic ovary syndrome: a randomized controlled trial. Fertil. Steril. 91(2), 514-521 (2009).
78. Legro RS, Barnhart HX, Schlaff WD et al.; Cooperative Multicenter Reproductive Medicine Network: Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. N. Engl. J. Med. 356(6), 551-566 (2007).
79. Kamber N, Davis WA, Bruce DG, Davis TM: Metformin and lactic acidosis in an Australian community setting: the Fremantle Diabetes Study. Med. J. Aust. 188, 446-449 (2008).
80. Legro RS, Kunselman AR, Dodson WC, Dunaif A: Prevalence and predictors of risk for Type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J. Clin. Endocrinol. Metab. 84, 165-169 (1999). (Pubitemid 29036695)
81. Palomba S, Falbo A, Orio F, Tolino A, Zullo F: Effcacy predictors for metformin and clomiphene citrate treatment in anovulatory infertile patients with polycystic ovary syndrome. Fertil. Steril. 91, 2557-2567 (2009).
82. Ibanez L, Valls C, Potau N, Marcos M V, de Zegher F: Sensitization to insulin in adolescent girls to normalize hirsutism, hyperandrogenism, oligomenorrhea, dyslipidemia, and hyperinsulinism after precocious pubarche. J. Clin. Endocrinol. Metab. 85, 3526-3530 (2000).
83. Salpeter SR, Buckley NS, Kahn JA, Salpeter EE: Meta-analysis: metformin treatment in persons at risk for diabetes mellitus. Am. J. Med. 121(2), 149-157 (2008).
84. Orchard TJ, Temprosa M, Goldberg R et al.; Diabetes Prevention Program Research Group. The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial. Ann. Intern. Med. 142(8), 611-619 (2005). (Pubitemid 40529957)
85. Pasquali R, Gambineri A, Biscotti D et al.: Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 85, 2767-2774 (2000). (Pubitemid 32269149)
86. Fauser BC, Diedrich K, Devroey P; on behalf of the Evian Annual Reproduction (EVAR) Workshop Group 2007: Predictors of ovarian response: progress towards individualized treatment in ovulation induction and ovarian stimulation. Hum. Reprod. Updat. 14, 1-14 (2008).
87. Tan S, Hahn S, Benson S et al.: Metformin improves polycystic ovary syndrome symptoms irrespective of pre-treatment insulin resistance. Eur. J. Endocrinol. 157, 669-676 (2007). (Pubitemid 350187385)
88. Yilmaz M, Biri A, Karakoc et al.: The effects of rosiglitazone and metformin on insulin resistance and serum androgen levels in obese and lean patients with polycystic ovary syndrome. J. Endocrinol. Invest. 28, 1003-1008 (2005). (Pubitemid 43265766)
89. Bruno RV, de Avila MA, Neves FB, Nardi AE, Crespo CM, Sobrinho AT: Comparison of two doses of metformin (2.5 and 1.5 g/day) for the treatment of polycystic ovary syndrome and their effect on body mass index and waist circumference. Fertil. Steril. 88, 510-512 (2007).
90. Chang WY, Knochenhauer ES, Bartolucci AA, Azziz R: Phenotypic spectrum of polycystic ovary syndrome: clinical and biochemical characterization of the three major clinical subgroups. Fertil. Steril. 83, 1717-1723 (2005). (Pubitemid 40824804)
91. Legro RS, Dunaif A: Menstrual disorders in insulin resistant states. Diabetes Spectr. 10, 185-190 (1997).
92. Goldzieher J W, Axelrod LR: Clinical and biochemical features of polycystic ovarian disease. Fertil. Steril. 14, 631-653 (1963).
93. Glueck CJ, Wang P, Fontaine R, Tracy T, Sieve-Smith L: Metformin to restore normal menses in oligo-amenorrheic teenage girls with polycystic ovary syndrome (PCOS). J. Adolesc. Health 29, 160-169 (2001). (Pubitemid 32755792)
94. Ibanez L, Valls C, Ferrer A, Marcos MV, Rodriguez-Hierro F, de Zegher F: Sensitization to insulin induces ovulation in nonobese adolescents with anovulatory hyperandrogenism. J. Clin. Endocrinol. Metab. 86, 3595-3598 (2001). (Pubitemid 32755948)
95. Morin-Papunen LC, Vauhkonen I, Koivunen RM, Ruokonen A, Martikainen HK, Tapanainen JS: Endocrine and metabolic effects of metformin versus ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study. J. Clin. Endocrinol. Metab. 85, 3161-3168 (2000).
96. Morin-Papunen L, Vauhkonen I, Koivunen R, Ruokonen A, Martikainen H, Tapanainen JS: Metformin versus ethinyl estradiol-cyproterone acetate in the treatment of nonobese women with polycystic ovary syndrome: a randomized study. J. Clin. Endocrinol. Metab. 88, 148-156 (2003). (Pubitemid 36115157)
97. Koivunen R, Pouta A, Franks S et al.; Northern Finland Birth Cohort 1966 Study: Fecundability and spontaneous abortions in women with self-reported oligo-amenorrhea and/or hirsutism: Northern Finland Birth Cohort 1966 Study. Hum. Reprod. 23, 2134-2139 (2008).
98. Moll E, Bossuyt PM, Korevaar JC, Lambalk CB, van der Veen F: Effect of clomifene citrate plus metformin and clomifene citrate plus placebo on induction of ovulation in women with newly diagnosed polycystic ovary syndrome: randomised double blind clinical trial. BMJ 332(7556), 1485 (2006). (Pubitemid 44365283)
99. Fulghesu AM, Villa P, Pavone V et al.: The impact of insulin secretion on the ovarian response to exogenous gonadotropins in polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 82, 644-648 (1997). (Pubitemid 27068644)
100. Rice S, Christoforidis N, Gadd C et al.: Impaired insulin-dependent glucose metabolism in granulosa-lutein cells from anovulatory women with polycystic ovaries. Hum. Reprod. 20, 373-381 (2005). (Pubitemid 40277604)
101. Khorram O, Helliwell JP, Katz S, Bonpane CM, Jaramillo L: Two weeks of metformin improves clomiphene citrate-induced ovulation and metabolic profles in women with polycystic ovary syndrome. Fertil. Steril. 85, 1448-1451 (2006).
102. Hwu YM, Lin SY, Huang WY, Lin MH, Lee RK: Ultra-short metformin pretreatment for clomiphene citrate-resistant polycystic ovary syndrome. Int. J. Gynaecol. Obstet. 90, 39-43 (2005). (Pubitemid 40909955)
103. Hock DL, Bohrer MK, Ananth CV, Kemmann E: Sonographic assessment of endometrial pattern and thickness in patients treated with clomiphene citrate, human menopausal gonadotropins, and intrauterine insemination. Fertil. Steril. 68, 242-245 (1997). (Pubitemid 27342595)
104. Pasquali R, Gambineri A, Pagotto U: The impact of obesity on reproduction in women with polycystic ovary syndrome. BJOG 13, 1148-1159 (2006). (Pubitemid 44401208)
105. Hermansen K, Mortensen LS: Body weight changes associated with antihyperglycaemic agents in Type 2 diabetes mellitus. Drug Saf. 30, 1127-1142 (2007). (Pubitemid 350172854)
106. Christ-Crain M, Kola B, Lolli F et al. AMP-activated protein kinase mediates glucocorticoid-induced metabolic changes: a novel mechanism in Cushing's syndrome. FASEB J. 22, 1672-1683 (2008). (Pubitemid 351811445)
107. Wu FCW, Eckardstein A: Androgens and coronary artery disease. Endocr. Rev. 24, 183-217 (2003). (Pubitemid 36515284)
108. UK Prospective Diabetes Study (UKPDS) Group: Effect of intensive blood-glucose control with metformin on complications in overweight patients with Type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352, 854-865 (1998). (Pubitemid 28416719)
109. Mellbin LG, Malmberg K, Norhammar A, Wedel H, Ryden L; DIGAMI 2 Investigators: The impact of glucose lowering treatment on long-term prognosis in patients with Type 2 diabetes and myocardial infarction: a report from the DIGAMI 2 trial. Eur. Heart J. 29, 166-176 (2008).
110. Calvert JW, Gundewar S, Jha S et al.: Acute metformin therapy confers cardioprotection against myocardial infarction via AMPK-eNOS-mediated signaling. Diabetes 57, 696-705 (2008).
111. Tang T, Glanville J, Hayden CJ, White D, Barth JH, Balen AH: Combined lifestyle modifcation and metformin in obese patients with polycystic ovary syndrome. A randomized, placebo-controlled, double-blind multicentre study. Hum. Reprod. 21, 80-89 (2006). (Pubitemid 41794294)
112. Balen AH, Tan SL, MacDougall J, Jacobs HS Miscarriage rates following in-vitro fertilization are increased in women with polycystic ovaries and reduced by pituitary desensitization with buserelin. Hum. Reprod. 8, 959-964 (1993). (Pubitemid 23193697)
113. Regan L, Braude PR, Trembath PL: Infuence of past reproductive performance on risk of spontaneous abortion. BMJ 299, 541-545 (1989). (Pubitemid 19212331)
114. Glueck CJ, Phillips H, Cameron D, Sieve-Smith L, Wang P: Continuing metformin throughout pregnancy in women with polycystic ovary syndrome appears to safely reduce frst-trimester spontaneous abortion: a pilot study. Fertil. Steril. 75, 46-52 (2001). (Pubitemid 32041226)
115. Radon PA, McMahon MJ, Meyer WR: Impaired glucose tolerance in pregnant women with polycystic ovary syndrome. Obstet. Gynecol. 94, 194-197 (1999). (Pubitemid 29352860)
116. Boomsma CM, Eijkemans MJ, Hughes EG, Visser GH, Fauser BC, Macklon NS: A meta-analysis of pregnancy outcomes in women with polycystic ovary syndrome. Hum. Reprod. Updat. 12, 673-683 (2006). (Pubitemid 44605508)
117. Norman RJ, Wang JX, Hague W: Should we continue or stop insulin sensitizing drugs during pregnancy? Curr. Opin. Obstet. Gynecol. 16, 245-250 (2004). (Pubitemid 38703840)
118. Glueck CJ, Goldenberg N, Wang P, Loftspring M, Sherman A: Metformin during pregnancy reduces insulin, insulin resistance, insulin secretion, weight, testosterone and development of gestational diabetes: prospective longitudinal assessment of women with polycystic ovary syndrome from preconception throughout pregnancy. Hum. Reprod. 19, 510-521 (2004). (Pubitemid 38344509)
119. Vanky E, Salvesen KA, Heimstad R, Fougner KJ, Romundstad P, Carlsen SM: Metformin reduces pregnancy complications without affecting androgen levels in pregnant polycystic ovary syndrome women: results of a randomized study. Hum. Reprod. 19, 1734-1740 (2004). (Pubitemid 39144614)
120. Moore LE, Briery CM, Clokey D et al.: Metformin and insulin in the management of gestational diabetes mellitus: preliminary results of a comparison. J. Reprod. Med. 52, 1011-1015 (2007). (Pubitemid 350305083)
121. Glueck CJ, Pranikoff J, Aregawi D, Wang P: Prevention of gestational diabetes by metformin plus diet in patients with polycystic ovary syndrome. Fertil. Steril. 89, 625-634 (2008). (Pubitemid 351337664)
122. Salvesen KA, Vanky E, Carlsen SM: Metformin treatment in pregnant women with polycystic ovary syndrome-is reduced complication rate mediated by changes in the uteroplacental circulation? Ultrasound Obstet. Gynecol. 29, 433-437 (2007). (Pubitemid 46632240)
123. Palomba S, Pasquali R, Orio F, Nestler JE: Clomiphene citrate, metformin or both as frst-step approach in treating anovulatory infertility in patients with polycystic ovary syndrome (PCOS): a systematic review of head-to-head randomized controlled studies and meta-analysis. Clin. Endocrinol. 70, 311-321 (2009).
124. Palomba S, Falbo A, Orio F, Zullo F: Effect of preconceptional metformin on abortion risk in polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials. Fertil. Steril. 92, 1646-1658 (2009).
125. Gilbert C, Valois M, Koren G: Pregnancy outcome after frst trimester exposure to metformin: a meta-analysis. Fertil. Steril. 86, 658-663 (2006). (Pubitemid 44307028)
126. Glueck CJ, Salehi M, Sieve L, Wang P: Growth, motor, and social development in breast-and formula-fed infants of metformin-treated women with polycystic ovary syndrome. J. Pediatr. 148, 628-632 (2006). (Pubitemid 43776894)
127. Costello MF, Eden JA: A systematic review of the reproductive system effects of metformin in patients with polycystic ovary syndrome. Fertil. Steril. 79, 1-13 (2003). (Pubitemid 36071228)
128. Lord JM, Flight IH, Norman RJ: Metformin in polycystic ovary syndrome: systematic review and meta-analysis. BMJ 327, 951-953 (2003).
129. Coffey S, Bano G, Mason HD: Health-related quality of life in women with polycystic ovary syndrome: a comparison with the general population using the Polycystic Ovary Syndrome Questionnaire (PCOSQ) and the Short Form-36 (SF-36). Gynecol. Endocrinol. 22, 80-86 (2006).
130. Kerchner A, Lester W, Stuart SP, Dokras A: Risk of depression and other mental health disorders in women with polycystic ovary syndrome: a longitudinal study. Fertil. Steril. 91, 207-212 (2009).
131. Hahn S, Janssen OE, Tan S et al.: Clinical and psychological correlates of quality-of-life in polycystic ovary syndrome. Eur. J. Endocrinol. 153, 853-860 (2005). (Pubitemid 43020236)
132. Elsenbruch S, Hahn S, Kowalsky D et al.: Quality of life, psychosocial well-being, and sexual satisfaction in women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 88, 5801-5807 (2003). (Pubitemid 38033054)
133. Hollinrake E, Abreu A, Maifeld M, Van Voorhis BJ, Dokras A: Increased risk of depression in women with polycystic ovary syndrome. Fertil. Steril. 87, 1369-1376 (2007). (Pubitemid 46829130)
134. Jones GL, Hall JM, Balen AH, Ledger WL: Health-related quality of life measurement in women with polycystic ovary syndrome: a systematic review. Hum. Reprod. Updat. 14, 15-25 (2008).
135. Ching HL, Burke V, Stuckey BG: Quality of life and psychological morbidity in women with polycystic ovary syndrome: body mass index, age and the provision of patient information are signifcant modifers. Clin. Endocrinol. 66, 373-379 (2007). (Pubitemid 46239296)
136. Janssen OE, Hahn S, Tan S, Benson S, Elsenbruch S: Mood and sexual function in polycystic ovary syndrome. Semin. Reprod. Med. 26, 45-52 (2008). (Pubitemid 351154916)
137. Hahn S, Benson S, Elsenbruch S et al.: Metformin treatment of polycystic ovary syndrome improves health-related quality-of-life, emotional distress and sexuality. Hum. Reprod. 21, 1925-1934 (2006). (Pubitemid 44028271)
138. Genazzani AR, Petraglia F, Bernardi F et al.: Circulating levels of allopregnanolone in humans: gender, age and endocrine infuences. J. Clin. Endocrinol. Metab. 83, 1-5 (1998). (Pubitemid 28496343)
139. Robel P, Baulieu EE: Neurosteroids: biosynthesis and function. Trends Endocrinol. Metab. 5, 1-8 (1994).
140. Mellon SH, Deschepper CF: Neurosteroid biosynthesis: genes for adrenal steroidogenic enzymes are expressed in the brain. Brain Res. 629, 283-292 (1993).
141. Holzbauer M, Birmingham MK, De Nicola AF, Oliver JT: In vivo secretion of 3a-hydroxy-5a-pregnan-20-one, a potent anesthetic steroid by the adrenal gland of the rat. J. Steroid Biochem. 22, 97-102 (1985). (Pubitemid 15130264)
142. Paul SM, Purdy RH: Neuroactive steroids. FASEB J. 6, 2311-2322 (1992).
143. Baulieu EE, Robel P: Neurosteroids: a new brain function? J. Steroid Biochem. Mol. Biol. 37, 395-403 (1990).
144. Jung-Testas I, Hu ZY, Baulieu EE, Robel P: Neurosteroids: biosynthesis of pregnenolone and progesterone in primarycultures of rat glial cells. Endocrinology 125, 2083-2091 (1989). (Pubitemid 19258646)
145. Akwa Y, Morfn RF, Robel P, Baulieu EE: Neurosteroid metabolism. Biochem. J. 288, 959-964 (1992).
146. Mellon SH: Neurosteroids: biochemistry, modes of action, and clinical relevance. J. Clin. Endocrinol. Metab. 78, 1003-1008 (1994). (Pubitemid 24143012)
147. A receptor function after acute stress. Neuroendocrinology 63, 166-172 (1996). (Pubitemid 26049628)
148. Barbaccia ML, Roscetti G, Trabucchi M et al.: The effects of inhibitors of GABAergic trasmission and stress on brain and serum allopregnanolone concentrations. Br. J. Pharmacol. 120, 1582-1588 (1997). (Pubitemid 27192452)
149. Palumbo MA, Salvestroni C, Gallo R et al.: Allopregnanolone concentration in hippocampus of prepubertal rats and female rats throughout estrous cycle. J. Endocrinol. Invest. 18, 853-856 (1995). (Pubitemid 26064022)
150. Genazzani AR, Palumbo MA, de Micheroux AA et al.: Evidence for a role for the neurosteroid allopregnanolone in the modulation of reproductive function in female rats. Eur. J. Endocrinol. 133, 375-380 (1995).
151. Genazzani AR, Salvestroni C, Guo A-L et al.: Neurosteroids and regulation of neuroendocrine function. In: The Brain: Source and Target for Sex Steroids Hormones. Genazzani AR, Petraglia F, Purdy RH (Eds), Parthenon, NY, USA 83-91 (1996).
152. Majewska MD: Neurosteroids: endogenous bimodal modulators of the GABA-A receptor. Mechanism of action and physiological signifcance. Prog. Neurobiol. 38, 379-395 (1992).
153. McEwen BS: Non-genomic and genomic effects of steroids on neural activity. Trends Pharmacol. Sci. 12, 141-147 (1991).
154. Baulieu EE, Schumacher M, Koenig H, Jung-Testas I, Akwa Y: Progesterone as a neurosteroid: actions within the nervous system. Cell Mol. Neurobiol. 16, 143-154 (1996). (Pubitemid 26158374)
155. Wang M, Seippel L, Purdy RH, Backstrom T: Relationship between symptom severity and steroid variation in women with premenstrual syndrome: study on serum pregnenolone sulfate, 5a-pregnan-3,20-dione and 3a-hydroxy-5a-pregnan-20- one. J. Clin. Endocrinol. Metab. 81, 1076-1082 (1996). (Pubitemid 126423246)
156. Schmidt PJ, Purdy RH, Moore PH, Paul SM, Rubinow DR: Circulating levels of anxiolytic steroids in the luteal phase in women with premenstrual syndrome and in control subjects. J. Clin. Endocrinol. Metab. 79, 1256-1260 (1994).
157. Genazzani AD, Chierchia E, Rattighieri E et al.: Metformin administration restores allopregnanolone response to ACTH stimulation in overweight hyperinsulinemic PCOS patients. Gynecol. Endocrinol. (2010) (In press).
158. Genazzani AD, Luisi M, Malavasi B et al.: Pulsatile secretory characteristics of allopregnanolone, a neuroactive steroid, during the menstrual cycle and in amenorrheic patients. Eur. J. Endocr. 146, 347-356 (2002). (Pubitemid 34257645)
159. Genazzani AD, Strucchi C, Luisi M et al.: Metformin administration modulates neurosteroid secretion in non-obese amenorrhoic patients with polycystic ovary syndrome. Gynecol. Endocrinol. 22, 36-43 (2006). (Pubitemid 43355096)